Search
Fosun Pharma Secures License Agreement with Neurocentria for AR1001 Drug Development in China
3 week ago /
Read about 0 minute
Author：小编
Fosun Pharma's holding subsidiary has entered into a licensing agreement with Neurocentria, acquiring exclusive rights to develop, register, manufacture, and market the AR1001 drug in China and Hong Kong/Macao. This agreement covers the use of AR1001 for the diagnosis, prevention, and treatment of Alzheimer's disease and other neurological disorders. As part of the deal, Fosun Pharma will make an initial payment of up to RMB 150 million, followed by regulatory milestone payments. AR1001 is an oral small molecule drug designed to slow the progression of Alzheimer's disease, and it currently stands as the only drug targeting this particular site not yet approved for global marketing.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
